It has been roughly eight months since my last Genmab (GMAB) article, where I highlighted the company's robust pipeline progress, strategic partnerships, and a strong 2023 performance, led by ...

Analysts' ratings for Genmab GMAB over the last quarter vary from bullish to bearish, as provided by 10 analysts. The following table provides a quick overview of their recent ratings ...

12 analysts have expressed a variety of opinions on Genmab (NASDAQ:GMAB) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...

Genmab GMAB will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Genmab to report an earnings ...

Genmab A/S (NASDAQ:GMAB), a Danish biotechnology company specializing in antibody therapeutics for cancer treatment, has been making waves in the pharmaceutical industry with its innovative ...

Management revised its revenue guidance upwards while lowering its expense forecast. Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising ...

Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody ...

“The third quarter of 2024 presented Genmab with additional opportunities to progress towards our goal of fundamentally transforming the lives of people with cancer and other serious disease ...

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab (GMAB – Research Report) and keeping the price target at $50.00. Ram Selvaraju’s rating is based on Genmab’s ...